Comparison of dipyridamole and fosinopril on renal progression in nephrectomized rats

Nephrology

Volumn 8, Issue 2, 2003, Pages 80-91

  Buranakarl, Chollada ^a   Kitjtawonrat, Anusak ^a   Pondeenana, Somchai ^a   Sunyasujaree, Boonmee ^a   Kanchanapangka, Sumolaya ^a   Chaiyabutr, Narongsak ^a   Bovée, Kenneth C ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dipyridamole; Fosinopril; Renal disease progression; Renal mass reduction rats

Indexed keywords

CALCIUM ION; CHLORIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPYRIDAMOLE; FOSINOPRIL; PHOSPHATE; POTASSIUM ION; SODIUM ION; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ELECTROLYTE BLOOD LEVEL; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HYPERTENSION; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; LIGATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA OSMOLALITY; PODOCYTE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; THROMBOCYTE AGGREGATION INHIBITION; UNINEPHRECTOMY; UREMIA; URINE OSMOLALITY; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIPYRIDAMOLE; DISEASE PROGRESSION; FOSINOPRIL; KIDNEY FAILURE; MALE; NEPHRECTOMY; PLATELET AGGREGATION INHIBITORS; RATS; RATS, WISTAR;

EID: 0038748034     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1797.2003.00141.x     Document Type: Article

References (45)

1. Purkerson ML, Joist JH, Yates J, Valdes A, Morrison A, Klahr S. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc. Natl Acad. Sci. USA 1985; 82: 193-7.
2. Zoja C, Benigni A, Livio M et al. Selective inhibition of platelet thromboxane generation with low dose aspirin does not protect rats with reduced renal mass from the development of progressive disease. Am. J. Pathol. 1989; 134: 1027-38.
3. Nakamura K, Kojima K, Arai T et al. Dipyridamole and dilazep suppress oxygen radicals in puromycin aminonucleoside nephrosis rats. Eur. J. Clin. Invest. 1998; 28: 877-83.
4. Kimura K, Endou H, Sakai F. Suppressive effect of dipyridamole on the proteinuria of aminonucleoside nephrosis in rat. J. Toxicol. Sci. 1979; 4: 1-10.
5. Purkerson ML, Joist JH, Yates J, Klahr S. Role of hypertension and coagulation in the progressive glomerulopathy of rats with subtotal renal ablation. Miner. Electrolyte Metab. 1987; 13: 370-6.
6. Brooks DP, Contino LC, Trizna W, Edwards RM, Ohlstein EH, Solleveld HA. Effect of enalapril or the thromboxane receptor antagonist, daltroban, in rats with subtotal renal ablation. J. Pharmacol. Exp. Ther. 1990; 253: 119-23.
7. Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J. Am. Soc. Nephrol. 1998; 9: 224-30.
8. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J. Clin. Invest. 1995; 96: 793-800.
9. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 1985; 76: 612-19.
10. Brun C. A rapid method for the determination of para-aminohippuric acid in kidney function test. J. Lab. Clin. Med. 1951; 37: 955-8.
11. Young MK Jr, Raisz LG. An anthrone procedure for determination of inulin in biological fluids. Proc. Soc. Exp. Biol. Med. 1952; 80: 771-4.
12. Moorehead UR, Biggs HG. 2-Amino-2 methyl-1-propanol as the alkalinizing agent in an improve of continuous flow cresolphthaline complex one procedure for calcium in serum. Clin. Chem. 1974; 20: 1458-60.
13. Gomori GA. Modification of the colorimetric phosphorus determination for use with the photoelectric colorimeter. J. Lab. Clin. Med. 1942; 27: 955-60.
14. Ritcher HJ, Lapointe YS. Urea in blood serum or urine (diacetyl mono-oxime procedure). Clin. Chem. 1962; 8: 335.
15. Hawk PB, Oser BL, Summerson WH. Practical Physiological Chemistry, 13th edn. New York: Blakinton, 1954.
16. Orisio S, Benigni A, Bruzzi I et al. Renal endothelin gene expression is increased in remnent kidney and correlates with disease progression. Kidney Int. 1993; 43: 354-8.
17. Tsuruda H, Okuda S, Onoyama K, Oh Y, Fujishima M. Effect of blood pressure on the progress of renal deterioration in rats with renal mass reduction. J. Lab. Clin. Med. 1986; 107: 43-50.
18. Cortes P, Zhao X, Riser BL, Narins RG. Regulation of glomerular volume in normal and partially nephrectomized rats. Am. J. Physiol. 1996; 270: F356-70.
19. Floege J, Bruns MW, Alpers CE et al. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnent kidney model. Kidney Int. 1992; 41: 297-309.
20. Zoja C, Perico N, Corna D et al. Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney. J. Am. Soc. Nephrol. 1990; 1: 799-807.
21. Prie D, Blanchet FB, Essig M, Jourdain JP, Friedlander G. Dipyridamole decreases renal phosphate leak and augments serum phosphorus in patients with low renal phosphate threshold. J. Am. Soc. Nephrol. 1998; 9: 1264-9.
22. Seikaly MG, Quigley R, Baum M. Effect of dipyridamole on serum and urinary phosphate in X-linked hypophosphatemia. Pediatr. Nephrol. 2000; 15: 57-9.
23. Redlak M, Szczepanska-Konkel M, Stepinski J, Angielski S. Effects of dipyridamole and furosemide on renal function during adenine dinucleotide infusion in rats. Acta Physiol. Pol. 1986; 37: 1-7.
24. Friedlander G, Couette S, Coureau C, Amiel C. Mechanisms whereby extracellular adenosine 3′ 5′-monophosphate inhibits phosphate transport in cultured opossum kidney cells and in rat kidney. Physiological implication. J. Clin. Invest. 1992; 90: 848-58.
25. Buranakarl C, Kijtawornrat A, Nampimoon P. Effects of Fosinopril on renal function, baroreflex response and noradrenaline pressor response in conscious normotensive dogs. Vet. Res. Comm. 2001; 25: 355-66.
26. DeForrest JM, Waldron TL, Harvey C et al. Blood pressure lowering and renal hemodynamic effects of fosinopril in conscious animal models. J. Cardiovasc. Pharmacol. 1990; 16: 139-46.
27. Bochicchio T, Sandoval G, Ron O, Perez-Grovas H, Bordes J, Herrera-Acosta J. Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int. 1990; 38: 873-9.
28. Sica DA, Cutler RE, Parmer RJ, Ford NF. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patient with chronic renal insufficiency. Clin. Pharmacokinet 1991; 20: 420-7.
29. Keilani T, Schlueter WA, Levin ML, Batlle DC. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann. Intern. Med. 1993; 118: 246-54.
30. Maschio G, Cagnoli L, Claroni F et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol. Dial. Transplant. 1994; 9: 265-9.
31. Brunner FP, Thiel G, Hermle M, Bock HA, Mihatsch MJ. Long-term enalaril and verapamil in rats with reduced renal mass. Kidney Int. 1989; 36: 969-77.
32. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 1992; 90: 766-71.
33. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 1986; 77: 1993-2000.
34. Raij L, Chiou XC, Owens R, Wrigley B. Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model. Am. J. Med. 1985; 79: 37-41.
35. Hall JE, Guyton AC, Jackson TE, Coleman TG, Lohmeier TE, Trippodo NC. Control of glomerular filtration rate by renin- angiotensin system. Am. J. Physiol. 1977; 233: F366-72.
36. Hsu CH, Kurtz TW, Slavicek JM. Effect of exogenous angiotensin II on renal hemodynamics in the awake rat. Circ. Res. 1980; 46: 646-50.
37. Myers BO, Deer WM, Brenner BM. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ. Res. 1975; 37: 101-10.
38. Edwards RM. Segmental effects of norepinephrine and angiotensin II on isolated renal microvessels. Am. J. Physiol. 1983; 244: F526-34.
39. Qiu C, Bayliss C. Endothelin and angiotensin mediated most glomerular responses to nitric oxide inhibition. Kidney Int. 1999; 55: 2390-6.
40. Duchin KL, Waclawski AP, Tu JI, Manning J, Frantz M, Willard DA. Pharmacokinetics, safety, and pharmocologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects. J. Clin. Pharmacol. 1991; 31: 58-64.
41. Murdoch D, McTavish D. Fosinopril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Drugs 1992; 43: 123-40.
42. Forslund T, Franzen P, Backman R. Comparison of fosinopril and hydrochlorothiazide in patients with mild to moderate hypertension. J. Intern. Med. 1991; 230: 511-17.
43. Gehr T, Sica D, Grasela D, Duchin K. Pharmacodynamics of fosinopril in chronic ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) patients. Clin. Pharmacol. Ther. 1991; 49: 194 (Abstract).
44. Keilani T, Schlueter W, Molteni A, Battle DC. Converting enzyme inhibition with fosinopril does not suppress plasma aldosterone and may not cause hyperkalemia despite moderate renal impairment. J. Hypertens. Suppl. 1992; 4:245 (Abstract).
45. Keilani T, Schlueter W, Batlle D. Selected aspects of ACE inhibitor therapy for patients with renal, disease: impact on proteinuria, lipids and potassium. J. Clin. Pharmacol. 1995; 35: 87-97.